Evidence map›Paper›PMID 37905147›Full record

ArticlebioRxiv : the preprint server for biology2024

Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs.

Schmidlin, Apodaca, Newell, Sastokas, Kinsler, Geiler-Samerotte

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

SchmidlinBiodesign Center for Mechanisms of Evolution, Arizona State University, Tempe, AZ.ORCID 0000-0001-6892-0928
ApodacaBiodesign Center for Mechanisms of Evolution, Arizona State University, Tempe, AZ.
NewellBiodesign Center for Mechanisms of Evolution, Arizona State University, Tempe, AZ.
SastokasBiodesign Center for Mechanisms of Evolution, Arizona State University, Tempe, AZ.
KinslerDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0001-8308-4665
Geiler-SamerotteBiodesign Center for Mechanisms of Evolution, Arizona State University, Tempe, AZ.ORCID 0000-0003-4666-2192

Funding

A quantitative examination of cellular mechanisms that modulate the impacts of genetic variation - Renewal - 1R35GM133674 · NIGMS · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI Kerry A Geiler-Samerotte · 2019 to 2026
$2.8M
NIGMS NIH HHS R35 GM133674
6 · The paper itself

Abstract

There is growing interest in designing multidrug therapies that leverage tradeoffs to combat resistance. Tradeoffs are common in evolution and occur when, for example, resistance to one drug results in sensitivity to another. Major questions remain about the extent to which tradeoffs are reliable, specifically, whether the mutants that provide resistance to a given drug all suffer similar tradeoffs. This question is difficult because the drug-resistant mutants observed in the clinic, and even those evolved in controlled laboratory settings, are often biased towards those that provide large fitness benefits. Thus, the mutations (and mechanisms) that provide drug resistance may be more diverse than current data suggests. Here, we perform evolution experiments utilizing lineage-tracking to capture a fuller spectrum of mutations that give yeast cells a fitness advantage in fluconazole, a common antifungal drug. We then quantify fitness tradeoffs for each of 774 evolved mutants across 12 environments, finding these mutants group into 6 classes with characteristically different tradeoffs. Their unique tradeoffs may imply that each group of mutants affects fitness through different underlying mechanisms. Some of the groupings we find are surprising. For example, we find some mutants that resist single drugs do not resist their combination, while others do. And some mutants to the same gene have different tradeoffs than others. These findings, on one hand, demonstrate the difficulty in relying on consistent or intuitive tradeoffs when designing multidrug treatments. On the other hand, by demonstrating that hundreds of adaptive mutations can be reduced to a few groups with characteristic tradeoffs, our findings may yet empower multidrug strategies that leverage tradeoffs to combat resistance. More generally speaking, by grouping mutants that likely affect fitness through similar underlying mechanisms, our work guides efforts to map the phenotypic effects of mutation.

Indexed as

azole resistanceDNA barcodesdrug resistancefitness profilesFitness tradeoffsgene-by-environment interactionsgenotype-phenotype mapmolecular mechanisms

Identifiers

PMID37905147
PMCPMC10614906

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.